Can Eli Lilly’s Growth Keep Justifying its Premium?

Eli Lilly and Company (NYSE:LLY) has delivered the kind of growth that helps explain why investors are willing to pay a premium for its shares. The stock has returned over 55% in the past 12 months, compared with a nearly 14% growth of the S&P 500. That multiple reflects substantial expectations for future profitability. With […]